Breast cancer trial aims to spare women unnecessary surgery
NCT ID NCT07498400
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer returns in the armpit area over three years. The goal is to reduce side effects like lymphedema and pain while maintaining safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Exemption of sentinel lymph node biopsy (procedure)
What this could lead to
If successful, this could allow many women with triple-negative or HER2-positive breast cancer to avoid an extra surgical procedure, reducing side effects like arm swelling and pain.
What could go wrong
This is a relatively small, early-phase study (216 participants). It is not yet clear if skipping the biopsy will lead to a higher chance of cancer returning in the lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xijing Hospital
Xi'an, China